Back to Directory

Elizabeth (Betsy) McFarland

Email

betsy.mcfarland@ucdenver.edu

Phone

303-724-3447

Institution

Children’s Hospital Colorado

Title

Professor of Pediatrics

Address

Univeristy of Colorado Denver
Department of Pediatrics
13123 E. 16th Ave. B055
Aurora, CO 80045
United States

Request an Update

Affiliated Studies

IMPAACT 2038: Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines B/HPIV3/RSV/PreF, B/HPIV3/RSV/PreF/TM, or Placebo, Delivered via Nasal Sprayer to HPIV3-Seronegative Children 6 to 24 Months of Age

DAIDS Number

TBD

Research Area

Complications & Comorbidities

Study Status

In Development

IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV

DAIDS Number

TBD

Research Area

Cure

Study Status

In Development

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

38962

Research Area

Treatment

Study Status

In Development

P1053: Evaluation PI-Containing vs. Non-PI-Containing Salvage Regimens.

DAIDS Number

10131

Research Area

Other

Study Status

Concluded

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30072

Research Area

Complications & Comorbidities

Study Status

Concluded

Show All